Antonio Profico

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

3rd Party Cookies

Latest Research & Publications

Taking STRIDES: The Value of Diagnostics Against AMR

Altering the Trajectory of HIV in Europe

Understanding the Full Value of Long-Acting Therapies: less is more?

An Analysis of NICE’s Optimised Decisions from 2015 to 2024

Analysing Global Immunisation Expenditure

The BRAVER Roadmap to Broader Assessment of the Value of Health Interventions in the Asia-Pacific Region

Challenges and Solutions for Budget Impact Analysis of Gene Therapies

The Importance of Diversity of Supply in Rare Diseases Markets

All Publications

External Expert Profile

Antonio Profico

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Share on Mastodon